98TH GENERAL ASSEMBLY
State of Illinois
2013 and 2014
SB1934
 
Introduced 2/15/2013, by Sen. Antonio Muņoz - Iris Y. Martinez - Pamela J. Althoff - Melinda Bush
 
SYNOPSIS AS INTRODUCED:
 

 
225 ILCS 85/19.5 new

     Amends the Pharmacy Practice Act. Provides that a pharmacist may substitute a prescription biosimilar  product for a prescribed biological product under certain circumstances. Provides that the Board shall adopt rules for compliance with these provisions. Effective immediately.
  


LRB098 10574 MGM 40827 b

FISCAL NOTE ACT MAY APPLY
 
 
A BILL FOR
 

  
SB1934LRB098 10574 MGM 40827 b


  
1    AN ACT concerning regulation.
  
 
2    Be it enacted by the People of the State of Illinois,
 
3represented in the General Assembly:
  
 
 
4    Section 5. The Pharmacy Practice Act is amended  by adding 
5Section 19.5 as follows:
 
6    (225 ILCS 85/19.5 new)
7    Sec. 19.5. Biosimilars products. 
8    (a) For the purposes of this Section:
9    "Biological product",  "biosimilar",  and "interchangeable"  
10have the same meanings as under Section 351 of the Public 
11Health Service Act (42 U.S.C. 262).
12    "Prescription", with respect to a biological product, 
13means a product that is subject to Section 503 (b) of the 
14Federal, Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)).
15    (b) A pharmacist may substitute a prescription biosimilar  
16product for a prescribed biological product only if:
17        (1) the biosimilar product has been determined by the 
18    United States Food and Drug Administration to be 
19    interchangeable with the prescribed  biological  product;
20        (2) the prescribing physician does not designate 
21    orally, in writing, or electronically that substitution is 
22    prohibited in a manner inconsistent with Section 25 of this 
23    Act;
 
 
SB1934- 2 -LRB098 10574 MGM 40827 b

1        (3) the pharmacy informs the patient of the 
2    substitution;
3        (4) the pharmacist informs the prescriber within 5 
4    business days of the substitution, including the name and 
5    manufacturer of the interchangeable biosimilar dispensed;
6        (5)  the pharmacy  retains a written record of the 
7    interchangeable biosimilar substitution for a period of no 
8    less than 5 years.
9    (c) The Board shall adopt rules for compliance with this 
10Section.
 
11
 
12    Section 99. Effective date. This Act takes effect upon 
13becoming law.